1-20 of 32
Johanna Lahdenranta
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract 5807: Bicycle Toxin Conjugates®for the treatment of solid tumors

Stephen J. Walsh, Johanna Lahdenranta, Philip Huxley, Gemma Mudd, Gavin Bennett, Amy Brown, Katerine an Rietschoten, Liuhong Chen, Heather Scott, Gabriella Ivanova-Berndt, Katarzyna Dzionek, Mike Rigby, Olga Burenkova, Phil Jeffrey, Paul Beswick, Michael Skynner, Nicholas Keen
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 5807.
https://doi.org/10.1158/1538-7445.AM2024-5807
Published: 22 March 2024
View article titled, Abstract 5807: Bicycle Toxin Conjugates®for the treatment of solid tumors
Journal Articles

Abstract 5301: Tumor-targeted activation of CD137 using Bicycles: New insights into mechanism of action and discovery of BT7455, a clinical candidate for the treatment of EphA2-expressing cancers

Johanna Lahdenranta, Kristen Hurov, Heather Cohen, Lia Luus, Cara Bray, Peter Brown, Anna Devlen, Carly Campbell, Matthew Gray, Mike Kelly, Gemma Mudd, Punit Upadhyaya, Sailaja Battula, Kelvin Zhang, Anne-Sophie Dugast, Kevin McDonnell, Phil Brandish, Nicholas Keen
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 5301.
https://doi.org/10.1158/1538-7445.AM2024-5301
Published: 22 March 2024
View article titled, Abstract 5301: Tumor-targeted activation of CD137 using <em>Bicycles</em>: New insights into mechanism of action and discovery of BT7455, a clinical candidate for the treatment of EphA2-expressing cancers
Journal Articles

Abstract 1832: EphA2-dependent CD137 agonism and anti-tumor efficacy by BT7455, a Bicycle tumor-targeted immune cell agonist®

Lia Luus, Kristen Hurov, Johanna Lahdenranta, Chinmayee Shah, Anna Devlen, Julia Kristensson, Peter Brown, Cara Bray, Heather Cohen, Carly Campbell, Gemma Mudd, Punit Upadhyaya, Kevin McDonnell, Hongmei Xu, Phil Jeffrey, Philip E. Brandish, Nicholas Keen
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 1832.
https://doi.org/10.1158/1538-7445.AM2023-1832
Published: 04 April 2023
View article titled, Abstract 1832: EphA2-dependent CD137 agonism and anti-tumor efficacy by BT7455, a <em>Bicycle</em> tumor-targeted immune cell agonist<sup>®</sup>
Journal Articles

Abstract 1826: In vivo evaluation of NK-TICA®, a novel Bicycle® tumor-targeted immune cell agonist (TICA) designed to engage NK cells

Lukas Stanczuk, Johanna Lahdenranta, Fay J. Dufort, Christopher J. Leitheiser, Punit Upadhyaya, Philip E. Brandish, Nicholas Keen
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 1826.
https://doi.org/10.1158/1538-7445.AM2023-1826
Published: 04 April 2023
View article titled, Abstract 1826: <em>In vivo</em> evaluation of NK-TICA®, a novel Bicycle® tumor-targeted immune cell agonist (TICA) designed to engage NK cells
Journal Articles

Abstract 4230: Modeling the cDC1 ex vivo and in vitro: Development and comparison of a conventional dendritic cell culture system for industry

Laura L. Goodfield, Johanna Lahdenranta, Heather Scott, Tamera Ashworth, Lia Luus, Anna F. Licht, Kevin McDonnell, Phil Brandish, Nicholas Keen
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 4230.
https://doi.org/10.1158/1538-7445.AM2022-4230
Published: 15 June 2022
View article titled, Abstract 4230: Modeling the cDC1 <em>ex vivo</em> and <em>in vitro</em>: Development and comparison of a conventional dendritic cell culture system for industry
Journal Articles

Abstract 1976: Development of a CD137 receptor occupancy assay to support the phase I/II study of BT7480, a Bicycle tumor-targeted immune cell agonist™ (Bicycle TICA®)

Heather Cohen, Drasti Kanakia, Johanna Lahdenranta, Punit Upadhyaya, Kristen Hurov, Julia Kristensson, Chintan Jobaliya, Greg Bannish, Adam Cotty, Kevin McDonnell, Sandra Hirschberg, Phil Brandish, Sebastien Hazard, Dominic Smethurst, Nicholas Keen, Stephen J. Blakemore
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 1976.
https://doi.org/10.1158/1538-7445.AM2022-1976
Published: 15 June 2022
View article titled, Abstract 1976: Development of a CD137 receptor occupancy assay to support the phase I/II study of BT7480, a <em>Bicycle</em> tumor-targeted immune cell agonist™ (<em>Bicycle</em> TICA®)
Journal Articles

Abstract 333: Activity of the erythropoietin-producing hepatocellular A2 receptor (EphA2) targeting Bicycle® Toxin Conjugate (BTC™) BCY6033 in EGFR inhibitor resistant non-small lung cancer (NSCLC) patient derived xenografts

Kenneth Ngo, Elena V. Ivanova, Tyler J. Teceno, Carly Campbell, Johanna Lahdenranta, Stephen J. Blakemore, Gavin Bennett, Pasi A. Jänne, Cloud P. Paweletz, Prafulla C. Gokhale
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 333.
https://doi.org/10.1158/1538-7445.AM2022-333
Published: 15 June 2022
View article titled, Abstract 333: Activity of the erythropoietin-producing hepatocellular A2 receptor (EphA2) targeting Bicycle® Toxin Conjugate (BTC™) BCY6033 in EGFR inhibitor resistant non-small lung cancer (NSCLC) patient derived xenografts
Journal Articles

Abstract 1319: Rapid accumulation of cytotoxic payload in tumor tissue drives BT5528 activity in tumor models

Johanna Lahdenranta, Gavin Bennett, Philip Huxley, Gemma Mudd, Punit Upadhyaya, Phil Jeffrey, Nicholas Keen
Journal: Cancer Research
Cancer Res (2021) 81 (13_Supplement): 1319.
https://doi.org/10.1158/1538-7445.AM2021-1319
Published: 01 July 2021
View article titled, Abstract 1319: Rapid accumulation of cytotoxic payload in tumor tissue drives BT5528 activity in tumor models
Journal Articles

Abstract LB008: Integrative surfaceome profiling identifies immunotherapeutic targets in osteosarcomas (OS); Preclinical testing of BT1769, an MT1-MMP-targeted Bicycle Toxin Conjugate, in OS by the Pediatric Preclinical Testing Consortium (PPTC)

Yifei Wang, Wendong Zhang, Zhongting Zhang, Xiangjun Tian, Rossana N. Lazcano Segura, Pooja Hingorani, Michael Roth, Jonathan Gill, Douglas Harrison, Zhaohui Xu, Jing Wang, Eric J. Earley, Stephen W. Erickson, Edward A. Kolb, Malcolm A. Smith, Peter Houghton, Raushan Kurmasheva, Tara Gelb, Philip Huxley, Johanna Lahdenranta, Gemma Mudd, Richard Gorlick
Journal: Cancer Research
Cancer Res (2021) 81 (13_Supplement): LB008.
https://doi.org/10.1158/1538-7445.AM2021-LB008
Published: 01 July 2021
View article titled, Abstract LB008: Integrative surfaceome profiling identifies immunotherapeutic targets in osteosarcomas (OS); Preclinical testing of BT1769, an MT1-MMP-targeted Bicycle Toxin Conjugate, in OS by the Pediatric Preclinical Testing Consortium (PPTC)
Journal Articles

Abstract 1728: Nectin-4-dependent immune cell stimulation and anti-tumor efficacy by BT7480, a Nectin-4/CD137 Bicycle®tumor-targeted immune cell agonist (TICA™)

Kristen Hurov, Johanna Lahdenranta, Punit Upadhyaya, Drasti Kanakia, Elizabeth Repash, Fanglei You, Jun Ma, Eric Haines, Heather Cohen, Kevin McDonnell, Philip E. Brandish, Phil Jeffrey, Nicholas Keen
Journal: Cancer Research
Cancer Res (2021) 81 (13_Supplement): 1728.
https://doi.org/10.1158/1538-7445.AM2021-1728
Published: 01 July 2021
View article titled, Abstract 1728: Nectin-4-dependent immune cell stimulation and anti-tumor efficacy by BT7480, a Nectin-4/CD137 <em>Bicycle</em>®tumor-targeted immune cell agonist (TICA™)
Journal Articles

Abstract 1724: Microinjection of Nectin-4/CD137 tumor-targeted immune cell agonist (TICA™) activates the local tumor microenvironment

Johanna Lahdenranta, Stephen J. Blakemore, Kristen Hurov, Marc O. Grenley, Punit Upadhyaya, Carly Campbell, Elizabeth Repash, Eric Haines, Philip E. Brandish, Richard A. Klinghoffer, Nicholas Keen
Journal: Cancer Research
Cancer Res (2021) 81 (13_Supplement): 1724.
https://doi.org/10.1158/1538-7445.AM2021-1724
Published: 01 July 2021
View article titled, Abstract 1724: Microinjection of Nectin-4/CD137 tumor-targeted immune cell agonist (TICA™) activates the local tumor microenvironment
Journal Articles

Abstract 6703: A fully synthetic EphA2/4-1BB tumor-targeted immune cell agonist (TICATM) induces tumor localized 4-1BB agonism

Sailaja Battula, Gemma Mudd, Punit Upadhyaya, Julia Kristensson, Marianna Kleyman, Elizabeth Repash, Jessica Kublin, Jun Ma, Eric Haines, Kristen Hurov, Liuhong Chen, Johanna Lahdenranta, Paul Beswick, Kevin McDonnell, Nicholas Keen
Journal: Cancer Research
Cancer Res (2020) 80 (16_Supplement): 6703.
https://doi.org/10.1158/1538-7445.AM2020-6703
Published: 15 August 2020
View article titled, Abstract 6703: A fully synthetic EphA2/4-1BB tumor-targeted immune cell agonist (TICA<sup>TM</sup>) induces tumor localized 4-1BB agonism
Journal Articles

Abstract 5552: BT7480, a novel fully synthetic tumor-targeted immune cell agonist (TICATM) induces tumor localized 4-1BB agonism

Kristen Hurov, Punit Upadhyaya, Johanna Lahdenranta, Jessica Kublin, Jun Ma, Elizabeth Repash, Marianna Kleyman, Julia Kristensson, Liuhong Chen, Eric Haines, Sailaja Battula, Kevin McDonnell, Nicholas Keen
Journal: Cancer Research
Cancer Res (2020) 80 (16_Supplement): 5552.
https://doi.org/10.1158/1538-7445.AM2020-5552
Published: 15 August 2020
View article titled, Abstract 5552: BT7480, a novel fully synthetic tumor-targeted immune cell agonist (TICA<sup>TM</sup>) induces tumor localized 4-1BB agonism
Journal Articles

Abstract 4481: BT5528, an EphA2-targeting Bicycle Toxin Conjugate (BTC): Profound efficacy without bleeding and coagulation abnormalities in animal models

Gavin S. Bennett, Amy Brown, Gemma Mudd, Johanna Lahdenranta, Nicholas Keen
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): 4481.
https://doi.org/10.1158/1538-7445.AM2019-4481
Published: 01 July 2019
View article titled, Abstract 4481: BT5528, an EphA2-targeting Bicycle Toxin Conjugate (BTC): Profound efficacy without bleeding and coagulation abnormalities in animal models
Journal Articles

Abstract 3257: Activation of CD137 using multivalent and tumor targeted Bicyclic peptides

Kristen E. Hurov, Punit Upadhyaya, Jessica Kublin, Xueyuan Zhou, Julia Kristensson, Rachid Lani, Gemma Mudd, Katerine van Rietschoten, Frank An, Johanna Lahdenranta, Liuhong Chen, Gavin Bennett, Kevin McDonnell, Peter Park, Nicholas Keen
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): 3257.
https://doi.org/10.1158/1538-7445.AM2019-3257
Published: 01 July 2019
View article titled, Abstract 3257: Activation of CD137 using multivalent and tumor targeted Bicyclic peptides
Journal Articles

Abstract A10: In silico design of biomarker-optimized drug combinations in ERBB2+ cancers

Jinyan Du, Daniel Kirouac, Johanna Lahdenranta, Ryan Overland, Matthew Onsum, Charlotte McDonagh
Journal: Cancer Research
Cancer Res (2013) 73 (19_Supplement): A10.
https://doi.org/10.1158/1538-7445.FBCR13-A10
Published: 15 May 2014
View article titled, Abstract A10: In silico design of biomarker-optimized drug combinations in ERBB2+ cancers
Journal Articles

Abstract 4633: MM-111, a bispecific HER2 and HER3 antibody, synergistically combines with trastuzumab and paclitaxel in preclinical models of gastric cancer.

Bo Zhang, Johanna Lahdenranta, Jinyan Du, Daniel Kirouac, Stephanie Nguyen, Ryan Overland, Violette Paragas, Arthur Kudla, Ulrik Nielsen, Charlotte McDonagh, Matthew Onsum
Journal: Cancer Research
Cancer Res (2013) 73 (8_Supplement): 4633.
https://doi.org/10.1158/1538-7445.AM2013-4633
Published: 15 April 2013
View article titled, Abstract 4633: MM-111, a bispecific HER2 and HER3 antibody, synergistically combines with trastuzumab and paclitaxel in preclinical models of gastric cancer.
Journal Articles

Anti–Vascular Endothelial Growth Factor Therapies as a Novel Therapeutic Approach to Treating Neurofibromatosis-Related Tumors

Hon Kit Wong, Johanna Lahdenranta, Walid S. Kamoun, Annie W. Chan, Andrea I. McClatchey, Scott R. Plotkin, Rakesh K. Jain, Emmanuelle di Tomaso
Journal: Cancer Research
Cancer Res (2010) 70 (9): 3483–3493.
https://doi.org/10.1158/0008-5472.CAN-09-3107
Published: 28 April 2010
View article titled, Anti–Vascular Endothelial Growth Factor Therapies as a Novel Therapeutic Approach to Treating Neurofibromatosis-Related Tumors
Open the PDF for Anti–Vascular Endothelial Growth Factor Therapies as a Novel Therapeutic Approach to Treating Neurofibromatosis-Related Tumors in another window
Includes: Supplementary data
Journal Articles

A “Vascular Normalization Index” as Potential Mechanistic Biomarker to Predict Survival after a Single Dose of Cediranib in Recurrent Glioblastoma Patients

A. Gregory Sorensen, Tracy T. Batchelor, Wei-Ting Zhang, Poe-Jou Chen, Priscilla Yeo, Meiyun Wang, Dominique Jennings, Patrick Y. Wen, Johanna Lahdenranta, Marek Ancukiewicz, Emmanuelle di Tomaso, Dan G. Duda, Rakesh K. Jain
Journal: Cancer Research
Cancer Res (2009) 69 (13): 5296–5300.
https://doi.org/10.1158/0008-5472.CAN-09-0814
Published: 01 July 2009
View article titled, A “Vascular Normalization Index” as Potential Mechanistic Biomarker to Predict Survival after a Single Dose of Cediranib in Recurrent Glioblastoma Patients
Open the PDF for A “Vascular Normalization Index” as Potential Mechanistic Biomarker to Predict Survival after a Single Dose of Cediranib in Recurrent Glioblastoma Patients in another window
Includes: Multimedia, Supplementary data
Journal Articles

Abstract #LB-94: A \#8220;vascular normalization index\#8221; as a mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients: Insights from a Phase II study

A. Gregory Sorensen, Tracy Batchelor, Marek Ancukiewicz, Wei-Ting Zhang, Poe-Jou Chen, Priscilla Yeo, Meiyun Wang, Dominique Jennings, Patrick Wen, Johanna Lahdenranta, Emmanuelle di Tomaso, Dan Duda, Rakesh Jain
Journal: Cancer Research
Cancer Res (2009) 69 (9_Supplement): LB-94.
Published: 01 May 2009
View article titled, Abstract #LB-94: A \#8220;vascular normalization index\#8221; as a mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients: Insights from a Phase II study